Clone:
PD1.3.1.3
Type of antibody:
Primary antibodies, Functional-grade antibodies
Isotype:
mouse IgG2bκ, mouse IgG2b
Applications:
FC, MICS, IF, IHC, ICC, FA
Alternative names:
PDCD1, PD1, SLEB2, hPD-1, hPD-l, hSLE1

Extended validation for CD279 (PD1) Antibody, anti-human

Specificity

Epitope competition
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Other clonesOverlap in epitope recognition with PD1.3.1.3
EH12.1++
EH12.2H7++
J105++
MIH4-
NAT105++
REA1165++
Cells were incubated with an excess of purified unconjugated CD279 (PD1) (PD1.3.1.3) antibody followed by staining with fluorochrome-conjugated antibodies of other known clones against the same marker. Based on the fluorescence signal obtained, the clones were identified as recognizing completely overlapping (++), partially overlapping (+), or completely different epitopes (-) of the marker.

Sensitivity

Performance comparison
Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.
View details
Flow cytometric comparison of different clones for CD279 (PD1). Human peripheral blood mononuclear cells (PBMCs) stimulated with CD3/CD28 antibodies (T Cell TransAct™) for 16 hours were stained with CD279 (PD1) antibodies and with a suitable counterstaining. As a control, CD279 (PD1) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD279 (PD1). Human peripheral blood mononuclear cells (PBMCs) stimulated with CD3/CD28 antibodies (T Cell TransAct™) for 16 hours were stained with CD279 (PD1) antibodies and with a suitable counterstaining. As a control, CD279 (PD1) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD279 (PD1). Human peripheral blood mononuclear cells (PBMCs) stimulated with CD3/CD28 antibodies (T Cell TransAct™) for 16 hours were stained with CD279 (PD1) antibodies and with a suitable counterstaining. As a control, CD279 (PD1) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD279 (PD1). Human peripheral blood mononuclear cells (PBMCs) stimulated with CD3/CD28 antibodies (T Cell TransAct™) for 16 hours were stained with CD279 (PD1) antibodies and with a suitable counterstaining. As a control, CD279 (PD1) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD279 (PD1). Human peripheral blood mononuclear cells (PBMCs) stimulated with CD3/CD28 antibodies (T Cell TransAct™) for 16 hours were stained with CD279 (PD1) antibodies and with a suitable counterstaining. As a control, CD279 (PD1) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD279 (PD1). Human peripheral blood mononuclear cells (PBMCs) stimulated with CD3/CD28 antibodies (T Cell TransAct™) for 16 hours were stained with CD279 (PD1) antibodies and with a suitable counterstaining. As a control, CD279 (PD1) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD279 (PD1). Human peripheral blood mononuclear cells (PBMCs) stimulated with CD3/CD28 antibodies (T Cell TransAct™) for 16 hours were stained with CD279 (PD1) antibodies and with a suitable counterstaining. As a control, CD279 (PD1) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Flow cytometric comparison of different clones for CD279 (PD1). Human peripheral blood mononuclear cells (PBMCs) stimulated with CD3/CD28 antibodies (T Cell TransAct™) for 16 hours were stained with CD279 (PD1) antibodies and with a suitable counterstaining. As a control, CD279 (PD1) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Fixation data
To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.
No fixation
Post fixation
View details
Comparison of staining pattern on non-fixed and fixed cells using CD279 (PD1) (PD1.3.1.3). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
View details
Comparison of staining pattern on non-fixed and fixed cells using CD279 (PD1) (PD1.3.1.3). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
Comparison of staining pattern on non-fixed and fixed cells using CD279 (PD1) (PD1.3.1.3). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD279 (PD1) Antibody, anti-human

Overview

PD1.3.1.3 recognizes human CD279, also known as programmed death-1 (PD-1). It is a 55 kDa transmembran protein belonging to the CD28/CTLA-4 family. It is expressed on T cells, B cells, NK cells, and activated myeloid cells. CD279 is not expressed on naive T cells but induced after activation and expressed on late, differentiated T cells. The ligands PD-L1 (B7-H1; CD274) and PD-L2 (B7-DC; CD273) belong to the B7 immunglobulin superfamily. PD1 and its ligands mediate inhibitory signals that regulate the balance between T cell activation, tolerance, and immunopathology. Clone PD.1.3.1.3 has been used to block the binding of both ligands.

Alternative names

PDCD1, PD1, SLEB2, hPD-1, hPD-l, hSLE1

Detailed product information

Technical specifications

ClonePD1.3.1.3
Clonalitymonoclonal
Isotypemouse IgG2bκ, mouse IgG2b
Isotype controlIsotype Control Antibody, mouse IgG2b
Hostmouse
Type of antibodyPrimary antibodies, Functional-grade antibodies
Specieshuman, non-human primate
Cross-reactivity
rhesus monkey (
Macaca mulatta
)
AntigenCD279 (PD1)
Alternative names of antigenPDCD1, PD1, SLEB2, hPD-1, hPD-l, hSLE1
Molecular mass of antigen [kDa]29
Distribution of antigenB cells, monocytes, T cells, thymocytes, spleen
Entrez Gene ID5133
RRIDAB_2728018, AB_2727977, AB_2727929, AB_2733366, AB_2733367, AB_2728045, AB_2728022, AB_2784104, AB_2784103, AB_10828445, AB_2728041

Resources for CD279 (PD1) Antibody, anti-human

Certificates

Please follow this
link
to search for Certificates of Analysis (CoA) by lot number.

References for CD279 (PD1) Antibody, anti-human

Publications

  1. Serriari, N.-E. et al. (2010) B and T lymphocyte attenuator is highly expressed on CMV-specific T cells during infection and regulates their function. J. Immunol. 185: 3140-3148
  2. Okazaki, T. and Honjo, T. (2007) PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 19: 813-824
  3. Keir, M. E. et al. (2008) PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26: 677-704

Related products for
CD279 (PD1) Antibody, anti-human

3 products available

Seems like you are coming from USA!
Do you want to visit our website in your country?